A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics

• Published in: PloS one Vol. 13; no. 3; p. e0194688
• Main Authors: Costa, Maria José, Kudaravalli, Jyothirmayee, Liu, Wen-Hui, Stock, Jeffrey, Kong, Sophanna, Liu, Shu-Hui
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 19.03.2018; Public Library of Science (PLoS)
• Subjects: Animal models; Animal tissues; Biocompatibility; Biological activity; Biology and Life Sciences; Blocking antibodies; Blood; Bone marrow; Cancer; Cancer immunotherapy; Cancer therapies; Chemokines; Clinical trials; Cloning; CXCR4 protein; Drug development; Drug dosages; Drug efficacy; Effectiveness; Evaluation; Gene expression; Health risks; Hematology; Homeostasis; Homing; Human performance; Human tissues; Immunization; Immunoglobulins; Immunology; In vivo methods and tests; Leukocyte migration; Leukocytes; Ligands; Medical research; Medicine and Health Sciences; Monoclonal antibodies; Oncology; Peripheral blood; Physiology; Primates; R&D; Research & development; Research and Analysis Methods; Rodents; Safety; Signaling; Stem cells; Toxicity; Tumors; Wound healing; Xenografts; Xenotransplantation; United States > US; South San Francisco California; California
• DOI: 10.1371/journal.pone.0194688
• ISSN: 1932-6203

The development of therapeutic monoclonal antibodies through mouse immunization often originates drug candidates that are not cross-reactive to the mouse ortholog. In such cases, and particularly in oncology, drug efficacy studies are performed on human tumor xenografts or with "surrogate" anti-mouse ortholog antibodies if targeting tumor host cells. Safety assessment of drug candidate(s) is performed at a later development stage in healthy non-human primates. While the latter remains necessary before a drug advances into human subjects, it precludes evaluation of safety in disease conditions and drug de-risking during early development. Therefore, mouse models that allow concomitant evaluation of drug efficacy and safety are highly desirable. The C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for tumor-targeted and immuno-oncology therapeutics, with multiple mouse immunization-derived antibodies undergoing clinical trials. Given the pleiotropic role of CXCR4 in cancer biology, we anticipate continuous interest in this target, particularly in the testing of therapeutic combinations for immuno-oncology. Here, we describe the generation and validation of the first mouse knock-in of the whole coding region of human CXCR4. Homozygous human CXCR4 knock-in (hereafter designated as HuCXCR4KI) mice were viable and outwardly healthy, reproduced normally and nursed their young. The expression pattern of human CXCR4 in this model was similar to that of CXCR4 expression in normal human tissues. The human CXCR4 knock-in gene was expressed as a biologically active protein, thereby allowing normal animal development and adequate"homing" of leukocytes to the bone marrow. To further validate our model, we used an in vivo functional assay of leukocyte mobilization from bone marrow to peripheral blood by blocking CXCR4 signaling. Both an anti-human CXCR4 -specific blocking antibody and the small molecule CXCR4 inhibitor AMD3100 induced increased leukocyte counts in peripheral blood, whereas an anti-mouse CXCR4 -specific blocking antibody had no effect. This new mouse model is useful to evaluate efficacy and safety of anti-human CXCR4 -specific drugs as single agents or in combination therapies, particularly in the oncology, immuno-oncology, wound healing and chronic inflammation therapeutic areas.